Wzy-dependent bacterial capsules as potential drug targets

Current Drug Targets

Volumn 13, Issue 11, 2012, Pages 1421-1431

  Ericsson, Daniel J ^a   Standish, Alistair ^b   Kobe, Bostjan ^a   Morona, Renato ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antibiotic resistance; Bacterial pathogens; Capsule; Drug discovery; Protein tyrosine kinase; Protein tyrosine phosphatase; Wzy

Indexed keywords

BACTERIAL POLYSACCHARIDE; PHOSPHOPROTEIN; PROTEIN CAPAB; PROTEIN CPSB; PROTEIN ETK; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN WZB; PROTEIN WZC; PROTEIN WZY; PROTEIN YWQE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACILLUS SUBTILIS; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BIOFILM; BIOSYNTHESIS; DRUG DESIGN; ESCHERICHIA COLI; NONHUMAN; PATHOGENICITY; REGULATORY MECHANISM; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SEQUENCE; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; VIRULENCE;

EID: 84866948321     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530279     Document Type: Review

References (111)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
3. World Health Organisation. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper 2007: 93-104.
4. Rudan I, Campbell H. The deadly toll of S. pneumoniae and H. influenzae type b. Lancet 2009; 374: 854-6.
5. McGee L, Klugman KP, Tomasz A. Serotypes and clones of antibiotic-resistant pneumococci. In: Streptococcus pneumoniae: Molecular Biology and Mechanisms of Disease, Mary Ann Liebert, inc.; 2000, pp. 375-9.
6. Green J, Ray S, Charney E. Recurrence rate of streptococcal pharyngitis related to oral penicillin. J Pediatr 1969; 75: 292-4.
7. Pechère JC. Patients' interviews and misuse of antibiotics. Clin Infect Dis 2001; 33 Suppl 3: S170-3.
8. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6: 288-301.
9. Yother J. Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu Rev Microbiol 2011; 65: 563-81.
10. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-73.
11. Norcross EW, Tullos NA, Taylor SD, Sanders ME, Marquart ME. Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection. Curr Eye Res 2010; 35: 787-98.
12. Weinberger DM, Harboe ZB, Sanders EAM, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51: 692-9.
13. MacLeod CM, Krauss MR. Relation of virulence of pneumococcal strains for mice to the quantity of capsular polysaccharide formed in vitro. J Exp Med 1950; 92: 1-9.
14. Morona JK, Morona R, Paton JC. Attachment of capsular polysaccharide to the cell wall of Streptococcus pneumoniae type 2 is required for invasive disease. Proc Natl Acad Sci USA 2006; 103: 8505-10.
15. Morona JK, Miller DC, Morona R, Paton JC. The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. J Infect Dis 2004; 189: 1905-13.
16. Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun 2007; 75: 83-90.
17. Magee AD, Yother J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 2001; 69: 3755.
18. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 2010; 78: 704-15.
19. Gross GN, Rehm SR, Pierce AK. The effect of complement depletion on lung clearance of bacteria. J Clin Invest 1978; 62: 373-8.
20. Brown JS, Hussell T, Gilliland SM, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 2002; 99: 16969-74.
21. Quin LR, Moore QC, McDaniel LS. Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect Immun 2007; 75: 2067-70.
22. Abeyta M, Hardy GG, Yother J. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 2003; 71: 218.
23. Dalia AB, Standish AJ, Weiser JN. Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun 2010; 78: 2108-16.
24. Hyams C, Opel S, Hanage W, et al. Effects of Streptococcus pneumoniae strain background on complement resistance. PloS One 2011; 6: e24581.
25. Dalia AB, Weiser JN. Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe 2011; 10: 486-96.
26. Melin M, Trzciński K, Meri S, Käyhty H, Väkeväinen M. The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun 2010; 78: 5262-70.
27. Hyams C, Yuste J, Bax K, Camberlein E, Weiser JN, Brown JS. Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun 2010; 78: 716-25.
28. Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009; 5: e1000476.
29. Lysenko ES, Lijek RS, Brown SP, Weiser JN. Within-host competition drives selection for the capsule virulence determinant of Streptococcus pneumoniae. Curr Biol 2010; 20: 1222-6.
30. Hammerschmidt S, Wolff S, Hocke A, Rosseau S, Müller E, Rohde M. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infect Immun 2005; 73: 4653.
31. Talbot UM, Paton AW, Paton JC. Uptake of Streptococcus pneumoniae by respiratory epithelial cells. Infect Immun 1996; 64: 3772.
32. Sanchez CJ, Hinojosa CA, Shivshankar P, et al. Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 2011; 6: e26587.
33. Moscoso M, García E, López R. Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. J Bacteriol 2006; 188: 7785-95.
34. Weiser JN, Austrian R, Sreenivasan PK, Masure HR. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 1994; 62: 2582-9.
35. Kim JO, Weiser JN. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 1998; 177: 368-77.
36. Kang YS, Kim JY, Bruening SA, et al. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc Natl Acad Sci USA 2004; 101: 215-20.
37. Lanoue A, Clatworthy MR, Smith P, et al. SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J Exp Med 2004; 200: 1383-93.
38. Wartha F, Beiter K, Albiger B, et al. Capsule and D-alanylated lipoteichoic acids protect Streptococcus pneumoniae against neutrophil extracellular traps. Cell Microbiol 2007; 9: 1162-71.
39. Fernebro J, Andersson I, Sublett J, et al. Capsular expression in Streptococcus pneumoniae negatively affects spontaneous and antibiotic-induced lysis and contributes to antibiotic tolerance. J Infect Dis 2004; 189: 328-38.
40. Standish AJ, Weiser JN. Human neutrophils kill Streptococcus pneumoniae via serine proteases. J Immunol 2009; 183: 2602-9.
41. Beiter K, Wartha F, Hurwitz R, Normark S, Zychlinsky A, Henriques-Normark B. The capsule sensitizes Streptococcus pneumoniae to alpha-defensins human neutrophil proteins 1 to 3. Infect Immun 2008; 76: 3710-6.
42. Llobet E, Tomás JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 2008; 154: 3877-86.
43. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10: 505-20.
44. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
45. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41.
46. Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000; 61: 1-10.
47. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and softtissue infections. Arch Intern Med 2008; 168: 1585-91.
48. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1: i29-36.
49. Melles DC, Taylor KL, Fattom AI, van Belkum A. Serotyping of Dutch Staphylococcus aureus strains from carriage and infection. FEMS Immunol Med Microbiol 2008; 52: 287-92.
50. Roghmann M, Taylor KL, Gupte A, et al. Epidemiology of capsular and surface polysaccharide in Staphylococcus aureus infections complicated by bacteraemia. J Hosp Infect 2005; 59: 27-32.
51. Sau S, Bhasin N, Wann ER, Lee JC, Foster TJ, Lee CY. The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology 1997; 143: 2395.
52. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17: 218-34.
53. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73: 3502.
54. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64: 1659.
55. Bae T, Banger AK, Wallace A, et al. Staphylococcus aureus virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc Natl Acad Sci USA 2004; 101: 12312-7.
56. Goller C, Seed PC. Revisiting the Escherichia coli polysaccharide capsule as a virulence factor during urinary tract infection: contribution to intracellular biofilm development. Virulence 2010; 1: 333-7.
57. Clements A, Tull D, Jenney AW, et al. Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem 2007; 282: 15569-77.
58. Clements A, Gaboriaud F, Duval JFL, et al. The major surfaceassociated saccharides of Klebsiella pneumoniae contribute to host cell association. PloS One 2008; 3: e3817.
59. Russo TA, Luke NR, Beanan JM, et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 2010; 78: 3993-4000.
60. Goller CC, Seed PC. High-throughput identification of chemical inhibitors of E. coli Group 2 capsule biogenesis as anti-virulence agents. PloS One 2010; 5: e11642.
61. Cuthbertson L, Mainprize IL, Naismith JH, Whitfield C. Pivotal roles of the outer membrane polysaccharide export and polysaccharide copolymerase protein families in export of extracellular polysaccharides in gram-negative bacteria. Microbiol Mol Biol Rev 2009; 73: 155-77.
62. Bentley SD, Aanensen DM, Mavroidi A, et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2: e31.
63. Varvio SL, Auranen K, Arjas E, Mäkelä PH. Evolution of the capsular regulatory genes in Streptococcus pneumoniae. J Infect Dis 2009; 200: 1144-51.
64. Liu D, Cole R. An O-antigen processing function for Wzx (RfbX): a promising candidate for O-unit flippase. J Bacteriol 1996; 178.
65. Morona R, Purins L, Tocilj A, Matte A, Cygler M. Sequencestructure relationships in polysaccharide co-polymerase (PCP) proteins. Trends Biochem Sci 2009; 34: 78-84.
66. Grangeasse C, Terreux R, Nessler S. Bacterial tyrosine-kinases: structure-function analysis and therapeutic potential. Biochim Biophys Acta 2010; 1804: 628-34.
67. Whitmore SE, Lamont RJ. Tyrosine phosphorylation and bacterial virulence. Int J Oral Sci 2012: 1-6.
68. Morona R, Van Den Bosch L, Daniels C. Evaluation of Wzz/MPA1/MPA2 proteins based on the presence of coiled-coil regions. Microbiology 2000; 146 (Pt 1): 1-4.
69. Hanson BR, Lowe BA, Neely MN. Membrane topology and DNAbinding ability of the Streptococcal CpsA protein. J Bacteriol 2011; 193: 411-20.
70. Eberhardt A, Hoyland CN, Vollmer D, et al. Attachment of capsular polysaccharide to the cell wall in Streptococcus pneumoniae. Microb Drug Resist 2012; 18(3): 240-55.
71. Morona JK, Paton JC, Miller DC, Morona R. Tyrosine phosphorylation of CpsD negatively regulates capsular polysaccharide biosynthesis in Streptococcus pneumoniae. Mol Microbiol 2000; 35: 1431-42.
72. Vincent C, Duclos B, Grangeasse C, et al. Relationship between exopolysaccharide production and protein-tyrosine phosphorylation in gram-negative bacteria. J Mol Biol 2000; 304: 311-21.
73. Niemeyer D, Becker A. The molecular weight distribution of succinoglycan produced by Sinorhizobium meliloti is influenced by specific tyrosine phosphorylation and ATPase activity of the cytoplasmic domain of the ExoP protein. J Bacteriol 2001; 183: 5163.
74. Nakar D, Gutnick DL. Involvement of a protein tyrosine kinase in production of the polymeric bioemulsifier emulsan from the oildegrading strain Acinetobacter lwoffii RAG-1. J Bacteriol 2003; 185: 1001.
75. Jadeau F, Bechet E, Cozzone AJ, Deléage G, Grangeasse C, Combet C. Identification of the idiosyncratic bacterial protein tyrosine kinase (BY-kinase) family signature. Bioinformatics 2008; 24: 2427-30.
76. Lee DC, Zheng J, She YM, Jia Z. Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism. EMBO J 2008; 27: 1758-66.
77. Bechet E, Gruszczyk J, Terreux R, et al. Identification of structural and molecular determinants of the tyrosine-kinase Wzc and implications in capsular polysaccharide export. Mol Microbiol 2010; 77: 1315-25.
78. Preneta R, Jarraud S, Vincent C, et al. Isolation and characterization of a protein-tyrosine kinase and a phosphotyrosine-protein phosphatase from Klebsiella pneumoniae. Comp Biochem Physiol B Biochem Mol Biol 2002; 131: 103-12.
79. Grangeasse C, Cozzone AJ, Deutscher J, Mijakovic I. Tyrosine phosphorylation: an emerging regulatory device of bacterial physiology. Trends Biochem Sci 2007; 32: 86-94.
80. Krissinel E, Henrick K. Protein interfaces, surfaces and assemblies service PISA at European Bioinformatics Institute. Available at http://www.ebi.ac.uk/pdbe/prot_int/pistart.html.
81. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372: 774-97.
82. Olivares-Illana V, Meyer P, Bechet E, et al. Structural basis for the regulation mechanism of the tyrosine kinase CapB from Staphylococcus aureus. PLoS Biol 2008; 6: e143.
83. Soulat D, Jault JM, Duclos B, Geourjon C, Cozzone AJ, Grangeasse C. Staphylococcus aureus operates protein-tyrosine phosphorylation through a specific mechanism. J Biol Chem 2006; 281: 14048-56.
84. Byrne JP, Morona JK, Paton JC, Morona R. Identification of Streptococcus pneumoniae Cps2C residues that affect capsular polysaccharide polymerization, cell wall ligation, and Cps2D phosphorylation. J Bacteriol 2011; 193: 2341-6.
85. Henriques MX, Rodrigues T, Carido M, Ferreira L, Filipe SR. Synthesis of capsular polysaccharide at the division septum of Streptococcus pneumoniae is dependent on a bacterial tyrosine kinase. Mol Microbiol 2011; 82: 515-34.
86. Hagelueken G, Huang H, Mainprize IL, Whitfield C, Naismith JH. Crystal structures of Wzb of Escherichia coli and CpsB of Streptococcus pneumoniae, representatives of two families of tyrosine phosphatases that regulate capsule assembly. J Mol Biol 2009; 392: 678-88.
87. Aravind L, Koonin EV. Phosphoesterase domains associated with DNA polymerases of diverse origins. Nucleic Acids Res 1998; 26: 3746-52.
88. Punta M, Coggill PC, Eberhardt RY, et al. The Pfam protein families database. Nucleic Acids Res 2011; 40: 290-301.
89. Kim HS, Lee SJ, Yoon HJ, et al. Crystal structures of YwqE from Bacillus subtilis and CpsB from Streptococcus pneumoniae, unique metal-dependent tyrosine phosphatases. J Struct Biol 2011; 175: 442-50.
90. Morona JK, Morona R, Miller DC, Paton JC. Streptococcus pneumoniae capsule biosynthesis protein CpsB is a novel manganesedependent phosphotyrosine-protein phosphatase. J Bacteriol 2002; 184: 577-83.
91. Bender MH, Cartee RT, Yother J. Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae. J Bacteriol 2003; 185: 6057-66.
92. Weiser JN, Bae D, Epino H, et al. Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae. Infect Immun 2001; 69: 5430.
93. Giammarinaro P, Paton JC. Role of RegM, a homologue of the catabolite repressor protein CcpA, in the virulence of Streptococcus pneumoniae. Infect Immun 2002; 70: 5454-61.
94. Carvalho SM, Kloosterman TG, Kuipers OP, Neves AR. CcpA ensures optimal metabolic fitness of Streptococcus pneumoniae. PLoS One 2011; 6: e26707.
95. Obadia B, Lacour S, Doublet P, Baubichon-Cortay H, Cozzone AJ, Grangeasse C. Influence of tyrosine-kinase Wzc activity on colanic acid production in Escherichia coli K12 cells. J Mol Biol 2007; 367: 42-53.
96. Schreiber M, Res I, Matter A. Protein kinases as antibacterial targets. Curr Opin Cell Biol 2009; 21: 325-30.
97. Grangeasse C, Doublet P, Vaganay E, et al. Characterization of a bacterial gene encoding an autophosphorylating protein tyrosine kinase. Gene 1997; 204: 259-65.
98. Cozzone AJ. Bacterial tyrosine kinases: novel targets for antibacterial therapy? Trends Microbiol 2009; 17: 536-43.
99. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450: 1001-9.
100. Kozakov D, Hall DR, Chuang G-yu, et al. Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci USA 2011; 108: 13528-33.
101. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 2009; 16: 706-33.
102. Beresford NJ, Mulhearn D, Szczepankiewicz B, et al. Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages. J Antimicrob Chemother 2009; 63: 928-36.
103. Rawls KA, Grundner C, Ellman JA. Design and synthesis of nonpeptidic, small molecule inhibitors for the Mycobacterium tuberculosis protein tyrosine phosphatase PtpB. Org Biomol Chem 2010; 8: 4066-70.
104. Zhou B, He Y, Zhang X, et al. Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci USA 2010; 107: 4573-8.
105. Tautz L, Bruckner S, Sareth S, et al. Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem 2005; 280: 9400-8.
106. Huang Z, He Y, Zhang X, et al. Derivatives of salicylic acid as inhibitors of YopH in Yersinia pestis. Chem Biol Drug Des 2010; 76: 85-99.
107. Standish AJ, Salim AA, Zhang H, Capon RJ, Morona R. Chemical inhibition of bacterial protein tyrosine phosphatase suppresses capsule production. PloS One 2012; 7(5): e36312.
108. Di Tommaso P, Moretti S, Xenarios I, et al. T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res 2011; 39: 13-7.
109. McNicholas S, Potterton E, Wilson KS, Noble MEM. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr D Biol Crystallogr 2011; 67: 386-94.
110. Krissinel E, Henrick K. Protein structure comparison service Fold at European Bioinformatics Institute. Available at http://www.ebi.ac.uk/msd-srv/ssm.
111. Velankar S, Best C, Beuth B, et al. PDBe: Protein Data Bank in Europe. Nucleic Acids Res 2010; 38: D308-17.